BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu J, Qian J, Yin S, Zhou L, Zheng S, Zhang W. Mechanisms of RNA N6-Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology. Front Oncol 2020;10:1105. [PMID: 32733807 DOI: 10.3389/fonc.2020.01105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Yuan B, Lu M, Wang Y, Ding N, Liu C, Gao M, Yao Z, Zhang S, Zhao Y, Xie L, Chen Z. The methyltransferase METTL3 negatively regulates nonalcoholic steatohepatitis (NASH) progression. Nat Commun 2021;12:7213. [PMID: 34893641 DOI: 10.1038/s41467-021-27539-3] [Reference Citation Analysis]
2 Fan C, Ma Y, Chen S, Zhou Q, Jiang H, Zhang J, Wu F. Comprehensive Analysis of the Transcriptome-Wide m6A Methylation Modification Difference in Liver Fibrosis Mice by High-Throughput m6A Sequencing. Front Cell Dev Biol 2021;9:767051. [PMID: 34869362 DOI: 10.3389/fcell.2021.767051] [Reference Citation Analysis]
3 Cruz J, Lemos B. Post-transcriptional diversity in riboproteins and RNAs in aging and cancer. Semin Cancer Biol 2021:S1044-579X(21)00224-8. [PMID: 34474152 DOI: 10.1016/j.semcancer.2021.08.012] [Reference Citation Analysis]
4 Zhang T, Sheng P, Jiang Y. m6A regulators are differently expressed and correlated with immune response of pancreatic adenocarcinoma. J Cancer Res Clin Oncol 2022. [PMID: 35780396 DOI: 10.1007/s00432-022-04150-7] [Reference Citation Analysis]
5 Qu N, Bo X, Li B, Ma L, Wang F, Zheng Q, Xiao X, Huang F, Shi Y, Zhang X. Role of N6-Methyladenosine (m6A) Methylation Regulators in Hepatocellular Carcinoma. Front Oncol 2021;11:755206. [PMID: 34692544 DOI: 10.3389/fonc.2021.755206] [Reference Citation Analysis]
6 Lin Y, Yao Y, Wang Y, Wang L, Cui H. PD-L1 and Immune Infiltration of m6A RNA Methylation Regulators and Its miRNA Regulators in Hepatocellular Carcinoma. Biomed Res Int 2021;2021:5516100. [PMID: 34055974 DOI: 10.1155/2021/5516100] [Reference Citation Analysis]
7 Ye M, Wang S, Qie JB, Sun PL. SPRY4-AS1, A Novel Enhancer RNA, Is a Potential Novel Prognostic Biomarker and Therapeutic Target for Hepatocellular Carcinoma. Front Oncol 2021;11:765484. [PMID: 34671565 DOI: 10.3389/fonc.2021.765484] [Reference Citation Analysis]
8 Klinge CM, Piell KM, Petri BJ, He L, Zhang X, Pan J, Rai SN, Andreeva K, Rouchka EC, Wahlang B, Beier JI, Cave MC. Combined exposure to polychlorinated biphenyls and high-fat diet modifies the global epitranscriptomic landscape in mouse liver. Environ Epigenet 2021;7:dvab008. [PMID: 34548932 DOI: 10.1093/eep/dvab008] [Reference Citation Analysis]
9 Li Q, Ren CC, Chen YN, Yang L, Zhang F, Wang BJ, Zhu YH, Li FY, Yang J, Zhang ZA. A Risk Score Model Incorporating Three m6A RNA Methylation Regulators and a Related Network of miRNAs-m6A Regulators-m6A Target Genes to Predict the Prognosis of Patients With Ovarian Cancer. Front Cell Dev Biol 2021;9:703969. [PMID: 34631700 DOI: 10.3389/fcell.2021.703969] [Reference Citation Analysis]
10 Guo T, He K, Wang Y, Sun J, Chen Y, Yang Z. Prognostic Signature of Hepatocellular Carcinoma and Analysis of Immune Infiltration Based on m6A-Related lncRNAs. Front Oncol 2021;11:691372. [PMID: 34527575 DOI: 10.3389/fonc.2021.691372] [Reference Citation Analysis]